Allan Bradley leads translation opportunity

Wellcome Trust Sanger Institute Director to focus on research and development

Allan Bradley leads translation opportunity

Professor Allan Bradley will step down as Director of the Institute to devote time to the development of a promising novel technology in mouse genetics.

The Wellcome Trust Sanger Institute announces today that Professor Allan Bradley will step down as Director of the Institute to devote time to the development of a promising novel technology in mouse genetics resulting from findings from his laboratory work. Professor Bradley will continue to lead a research lab at the Institute as one of the Institute's Faculty of leading researchers.

Professor Mike Stratton, Deputy Director, will take over interim leadership of the Institute.

As one of the researchers who first developed mouse stem cell knockout methods with Martin Evans and Liz Robertson, Professor Bradley has always maintained an active research group. One area of his research has led to a translation opportunity, which will involve the creation of a new start-up company in the Cambridge area with significant investment from the Wellcome Trust.

Professor Bradley has decided to invest time and expertise in this start-up and his oversight will help to ensure that the methods and resources he and his team have produced are developed successfully.

Professor Bradley was appointed Director in 2000, taking on the challenge, responsibility and opportunity from founding Director John Sulston. He has steered the Institute through dramatic change into a new era of research.

"I had always envisaged that evolving the Institute's scientific portfolio to its current state would take about a decade. Over the last year, I have become convinced that to a great extent I had realized the vision I brought to the Sanger in 2000, a view reinforced by the overwhelmingly positive feedback I have enjoyed from the Governors and staff of the Trust over the last few years."

Professor Allan Bradley, current Director of the Wellcome Trust Sanger Institute

Professor Bradley built a Faculty of around 40 researchers whose work would exploit the genomic sequences of organisms to develop biological understanding and potential healthcare benefits. Under his leadership the Institute forged new partnerships in human genetics, informatics, pathogen genetics and mouse and zebrafish genetics: the numbers of research papers published has increased fivefold.

"On behalf of the Wellcome Trust I wish to thank Allan Bradley for his exceptional personal contribution to the success of the Sanger Institute over the last decade and to wish him every success in his continuing research programme at the Institute and in his new business venture."

"Under the leadership of Allan Bradley the Wellcome Trust Sanger Institute has been transformed following the magnificent achievement of the Human Genome Project into its current position as one of the world's leading research institutes devoted to understanding important aspects of genetic variation and gene function. This success has been a source of pride to the Wellcome Trust, and is a great credit to Allan and the staff of the Institute."

Sir Mark Walport, Director of the Wellcome Trust ​

Professor Stratton joined the Institute in 2000 and has been Deputy Director since 2007. He leads the highly successful Cancer Genome Project and is a leader of the International Cancer Genome Consortium.

Notes to Editors
Selected Websites
Contact the Press Office

Emily Mobley, Media Manager

Tel +44 (0)1223 496 851

Dr Samantha Wynne, Media Officer

Tel +44 (0)1223 492 368

Dr Matthew Midgley, Media Officer

Tel +44 (0)1223 494 856

Wellcome Sanger Institute,
CB10 1SA,

Mobile +44 (0) 7748 379849

Recent News

Appointments and changes to the Genome Research Limited Board
At the GRL Board meeting on 2 December 2019, David Willetts announced his intention to step down as Chair because of his extensive commitments across the academic and science sectors. Wellcome's Director, Jeremy Farrar, will take over the Chair of GRL Board from 1 January 2020.
Researchers identify new possibilities for the treatment of inflammatory bowel disease
Two molecular pathways found to be integral to maintaining balance in the digestive system
Root of childhood kidney cancer discovered
Pre-cancerous signatures found in healthy tissue point the way towards new treatment options